Guardant Health
GH
Guardant Health (GH) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.90
- EPS estimate
- −$0.76
- EPS surprise
- −18.14%
- Revenue surprise
- +6.60%
- Revenue
- $335.0M
- Revenue estimate
- $314.2M
- Reported
- Jul 30, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 30, 2026 | −$0.76 | −$0.90 | −18.14% | $335.0M | SEC |
| Q1 2026 | May 7, 2026 | −$0.81 | −$0.85 | −5.46% | $301.7M | SEC |
| Q4 2025 | Feb 19, 2026 | −$0.77 | −$1.00 | −30.41% | $281.3M | SEC |
| Q3 2025 | Oct 29, 2025 | −$0.79 | −$0.74 | +6.28% | $265.2M | SEC |
| Q2 2025 | Jul 30, 2025 | −$0.74 | −$0.80 | −8.04% | $232.1M | SEC |
| Q1 2025 | Apr 30, 2025 | −$0.79 | −$0.77 | +2.00% | $203.5M | SEC |
| Q4 2024 | Feb 20, 2025 | −$0.78 | −$0.90 | −15.80% | $201.8M | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.73 | −$0.88 | −20.48% | $191.5M | SEC |
| Q2 2024 | Aug 7, 2024 | −$0.75 | −$0.84 | −11.48% | $177.2M | SEC |
| Q1 2024 | May 9, 2024 | −$0.88 | −$0.94 | −6.92% | $168.5M | SEC |
| Q4 2023 | Feb 22, 2024 | −$0.86 | −$1.58 | −83.27% | $155.1M | SEC |
| Q3 2023 | Nov 6, 2023 | −$0.97 | −$0.73 | +24.55% | $143.0M | SEC |
| Q2 2023 | Aug 3, 2023 | −$1.22 | −$0.67 | +44.96% | $137.2M | SEC |
| Q1 2023 | May 9, 2023 | −$1.34 | −$1.30 | +2.82% | $128.7M | SEC |
| Q4 2022 | Feb 23, 2023 | −$1.40 | −$1.36 | +2.95% | $126.9M | SEC |
| Q3 2022 | Nov 3, 2022 | −$1.28 | −$1.58 | −23.38% | $117.4M | SEC |
| Q2 2022 | Aug 4, 2022 | −$1.21 | −$2.25 | −85.32% | $109.1M | SEC |
| Q1 2022 | May 5, 2022 | −$1.21 | −$1.21 | +0.27% | $96.1M | SEC |
| Q4 2021 | Feb 23, 2022 | −$1.11 | −$0.89 | +19.70% | $108.1M | SEC |
| Q3 2021 | Nov 4, 2021 | −$0.88 | −$1.06 | −20.03% | $94.8M | SEC |
Quarterly revenue
Frequently asked questions
When did Guardant Health (GH) last report earnings?
Guardant Health last reported on Jul 30, 2026, covering fiscal Q2 2026.
Did GH beat earnings estimates?
No. Guardant Health reported EPS of −$0.90 for Q2 2026 against a −$0.76 estimate — a 18.14% miss.
How much revenue did GH report last quarter?
Guardant Health reported $335.0M in revenue for Q2 2026, against a consensus estimate of $314.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.